Latest papers

[Dengue vaccines].

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation.

Dengue fever: a call for local, national, and international action.

Dengue vaccines for travelers.

Dengue fever in Rio: Macumba versus Voltaire.

Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys.

Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Towards a dengue vaccine: Progress to date and remaining challenges

The demand for a dengue vaccine: a contingent valuation survey in Metro Manila.

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Biological characteristics of dengue virus and potential targets for drug design.

Vaccinations in disease models with antibody-dependent enhancement.

Dengue and hemorrhagic fever: a potential threat to public health in the United States.

Dengue vaccine: opportunities and challenges.

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.

Dengue and yellow fever--challenges for the development and use of vaccines.